All Online

1 - 12 of 14 results

Refine

Active filters

Cardiovascular Risk in Diabetes
1 CME CREDIT

As the incidence of diabetes and obesity continue to grow, more Americans will develop serious complications and experience premature mortality from cardiometabolic causes. This session will enable you to stay up to date on recent groundbreaking research and management guideline updates that could change the way you treat your patients with diabetes, obesity, and/or dyslipidemia.


GLP-1 Receptor Agonists: A Podcast Series

0.75 CME/MOC
0.85 AANP | 0.85 Pharmacology

This podcast series will provide you with on the go learning covering the key points about GLP-1 receptor agonists (GLP-1 RAs). Dr. Michelle Magee will focus on barriers that patients may face to starting a GLP-1 RA and common questions that emerge in patient teaching. Cardiologist Ty Gluckman will take a deep dive into the cardiology benefits and indications for GLP-1 RAs. A FAQ session with Dr. Richard Pratley will answer Pri-Med learner questions about GLP-1 RAs.


0.25 CME CREDIT

GLP-1 Receptor Agonists: Overcoming Barriers (Podcast)

0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology

With the growing role of GLP-1 RAs in the management of diabetes, primary care providers are likely to find themselves discussing this class of medications with their patients. In this podcast, Dr. Michelle Magee will focus on barriers that patients may face to starting a GLP-1 RA and common questions that emerge in patient teaching. Faculty will review ways to troubleshoot these challenges and empower the clinician to engage in effective dialogue around this drug class. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 11/18/2020 and they are subject to change as new information is published.


0.25 CME CREDIT

GLP-1 Receptor Agonists: A Cardiology Perspective (Podcast)

0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology

In this podcast, cardiologist Ty Gluckman will take a deep dive into the cardiology benefits of glucagon like peptide-1 receptor agonists (GLP-1 RA). He will review the clinical trial data which has resulted in GLP-1 RA incorporation into guidelines, which address patients who have both diabetes and atherosclerotic cardiovascular disease. Dr. Gluckman will bring the perspective of a cardiologist into the discussion of these agents with emerging significance in cardiovascular risk reduction.


0.5 CME CREDIT

In this clinical coffee break, cardiologist Ty Gluckman and endocrinologist Archana Sadhu will explain why glucagon like peptide-1 receptor agonists (GLP-1 RA) are becoming increasingly prominent in diabetes algorithms and cardiovascular risk reduction. Faculty will review the clinical trial data on this class of medications as well as the mechanisms by which GLP-1 RA provide cardiovascular benefit. You will have the opportunity to engage with this activity, viewing resources and testing your knowledge with interactive questions and cases.


1 CME CREDIT

During this clinical coffee break, Dr. M. Susan Burke, and Elizabeth Haftel, a clinical pharmacist and certified diabetes educator, will discuss practical strategies for using GLP-1 receptor agonists in your patients with diabetes. They will discuss how this class of medications can benefit certain patients. To illustrate the process, faculty will walk through a patient case. You will have the opportunity to engage with this activity, view resources and test your knowledge with interactive questions.


0.5 CME CREDIT

Jeopardy! GLP-1 RA Edition

0.50 CME
0.41 AANP | 0.41 Pharmacology

Think you know it all about GLP-1 receptor agonists? Test your familiarity with these dynamic diabetes drugs in Jeopardy game show. This interactive game will allow you to showcase your knowledge on GLP-1 RA pharmacodynamics, clinical indications, cardiovascular benefits, and more. There will be a rationale following each question, ensuring that you have answers to take back to your practice. Please note that any data, indications, and guidelines presented in this activity are current as of 08/14/20 and they are subject to change as new information is published.


0.5 CME CREDIT

Jeopardy! Using GLP-1 RAs in the Clinic

0.50 CME/MOC
0.50 AANP | 0.50 Pharmacology

Step into the clinic and onto the game show floor! In this interactive game of Jeopardy! test your knowledge of GLP-1 RAs in various patient encounters where you can implement your knowledge of type 2 diabetes management algorithms and use shared decision with patients. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 09/30/2020 and they are subject to change as new information is published.


Nurse explaining the use of diabetic equipment to a patient
0.5 CME CREDIT

Time to meet your new patient! In this interactive activity, you will be guided through the case of a patient with type 2 diabetes at high-risk for atherosclerotic cardiovascular disease (ASCVD) via a series of questions and complementary videos. Questions will test your strengths and weaknesses around diabetes management, with some questions and feedback tailored directly to your management choices. After each question, you will be presented with learning moments designed to help increase your confidence managing patients with type 2 diabetes and reducing cardiovascular risk.


1 CME CREDIT

Over ten percent of the U.S. population suffers disproportionate cardiometabolic risk because of their type 2 diabetes (T2DM). In light of recent data, GLP-1 receptor agonists (GLP-1 RAs) have taken on a more prominent role in T2DM management algorithms. This session will discuss how you can distinguish among GLP-1 RAs and use them in your practice to help manage the risks that these patients face beyond glucose control. A member of the Diabetes Sisters organization will also be joining us to discuss their experience with starting a GLP-1 RA as a patient.


This short curriculum cuts to the heart of primary and secondary cardiovascular disease prevention in people with type 2 diabetes. The following two activities will help you individualize treatment and optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. This curriculum includes: • 1 educational video webcast • 1 simulated digital “tele-visit” with a standardized patient Pri-Med has partnered with RealCME to offer the Pri-Med community the innovative opportunity to schedule time for a simulated digital “tele-visit” with a standardized patient (SP), who is trained to simulate the symptoms and characteristics of patients you see in your practice. This interactive session is designed to complement the “Heart of the Matter” video webcast by enabling you to practice shared-decision making. You can benefit from scheduling this activity after viewing the educational webcast, but you are also welcome to sign up for this simulated digital tele-visit activity without viewing the webcast. The “patient” is a 52-year-old who is following up with you for their type 2 diabetes, with a history of obesity, hypertension, hypercholesterolemia, and coronary artery disease. The patient is on maximum dose of metformin, with an A1c today of 8.6%. A highly experienced observer will review your session and send you feedback via a customized scorecard. There is no cost for this activity, but there are limited sessions available. To schedule your free virtual visit, you will need this access code: PriMed2020 Link to activity: https://m.pri-med.com/T1ZMR080r000iMb30E5hYA0 Access code: PriMed2020


1 CME CREDIT

Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/26/2020, and they are subject to change as new information is published.